FBIO — Fortress Biotech Income Statement
0.000.00%
Last trade - 00:00- $91.02m
- -$85.27m
- $63.26m
Annual income statement for Fortress Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 68.8 | 75.7 | 84.5 | 57.7 | 63.3 |
| Cost of Revenue | |||||
| Gross Profit | 36.7 | 45 | 57.9 | 36.8 | 42.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 257 | 279 | 230 | 168 | 106 |
| Operating Profit | -189 | -204 | -146 | -110 | -43.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -164 | -213 | -154 | -121 | -33.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -165 | -214 | -154 | -121 | -32.9 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -64.7 | -86.6 | -60.6 | -46 | 6.82 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -64.7 | -94.6 | -68.7 | -55.9 | -1.88 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -10.7 | -16 | -7.95 | -2.72 | -0.699 |